Dexasone
Plasma Cell Neoplasm
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Hellenic Society of Hematology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05573802CT.gov A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05647512CT.gov Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | — | Withdrawn | — | — | — |
NCT05581875CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | — | Not Yet Recruiting | — | — | — |
NCT05298683CT.gov A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | — | Unknown | — | — | — |
NCT05280275CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | — | Unknown | — | — | — |
NCT05147493CT.gov A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | — | Unknown | — | — | — |
NCT00790842CT.gov Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction | — | Terminated | — | — | — |
NCT00729118CT.gov Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Hellenic Society of Hematology | P3 | BBB · 72 |
| Lenalidomide | Hellenic Society of Hematology | P3 | BBB |
| Cyclophosphamide | Affiliated Hospital to Academy of Military Medical Sciences | P3 | BB |
| Fludarabine | Affiliated Hospital to Academy of Military Medical Sciences | P3 | BB |
| Nivestim | Hellenic Society of Hematology | P3 | BB |
| Methotrexate | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Tacrolimus | Dartmouth-Hitchcock Medical Center | P3 | BB |
| Busulfanum | Baylor College of Medicine | P2 | B |
| Melphalan | Roswell Park Cancer Institute | P2 | B |
+41 more in the Plasma Cell Neoplasm cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in Plasma Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-plasma-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →